Comparative Pharmacology
Head-to-head clinical analysis: MYTREX A versus SULFACETAMIDE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX A versus SULFACETAMIDE SODIUM.
MYTREX A vs SULFACETAMIDE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate inhibits dihydrofolate reductase, leading to depletion of tetrahydrofolate and inhibition of DNA synthesis and cell proliferation. Also has immunomodulatory effects via adenosine release.
Competitively inhibits dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Methotrexate (MYTREX A) 7.5-25 mg orally once weekly, or 15-25 mg intramuscularly/subcutaneously once weekly for rheumatoid arthritis; in oncology, dosing varies per protocol.
1-2 drops of 10-30% solution into the conjunctival sac every 2-3 hours initially, tapering as infection resolves. Ointment: 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in normal renal function; prolonged to 24-30 hours in moderate to severe renal impairment (CrCl <30 mL/min).
7-12.8 hours (prolonged in renal impairment; requires dosing adjustment in CrCl <50 mL/min).
Renal: 90% unchanged drug; fecal: <10% via bile; minor hepatic metabolism to inactive metabolites.
Renal: 85-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category A/B
Sulfonamide Antibiotic
Sulfonamide Antibiotic